—
C+
C+ The full Closelook — membership. Open the C+ overview

Bausch + Lomb Corp (BLCO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Bausch + Lomb Corp

BLCO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bausch + Lomb operates as an eye health company, selling across three segments: Vision Care, Pharmaceuticals and Surgical. Vision Care covers contact lenses, lens-care products, vitamins and over-the-counter eye drops. Pharmaceuticals covers treatments for glaucoma, inflammation, dry eye and retinal disease. Surgical covers cataract, corneal, vitreous and retinal devices, including intraocular lenses and phacoemulsification equipment. It sells through direct sales forces and distributors, is headquartered in Vaughan, Canada, and operates as a subsidiary of Bausch Health Companies.
Where it sits in the stack
Bausch + Lomb holds no seat in Rubin, our AI build-out index; it sits in our broader universe under healthcare, in the medical instruments and supplies sector.
Who it is priced against
No peer group is set for this name in our coverage; the comparison the market draws is with Alcon, another eye-care company spanning vision care, pharmaceuticals and surgical devices.
Why Closelook tracks it
Bausch + Lomb holds no seat in Rubin or our other indices, and it carries no Closelook score; coverage here rests on price and chart structure alone.
What the diary watches
Whether the segment mix shifts, as the diary watches whether Surgical grows relative to Vision Care and Pharmaceuticals, and whether the recent chart pullback continues or steadies.

Bausch + Lomb Corp (BLCO) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 35/100 composite (momentum 60, quality 27, valuation 51) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BLCO, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Medical Instruments & Supplies · 8 names with week and year-to-date

Peer group

Medical Instruments & Supplies

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against BLCO on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BLCO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +0.6% in FY2025 149 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Bausch + Lomb Corp (BLCO)?

Bausch + Lomb Corp trades as BLCO on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is BLCO in a Closelook index?

Not currently — Bausch + Lomb Corp is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Bausch + Lomb Corp's Closelook composite score?

35 out of 100, with momentum 60, quality 27 and valuation 51 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BLCO trade against its moving averages?

Uptrend stack intact: Trades +2.2% vs the 50-day and +4.1% vs the 200-day average, 8.4% below the 52-week high and +25.8% off the 52-week low; a golden cross printed 18 sessions ago. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Bausch + Lomb Corp do?

Bausch + Lomb operates as an eye health company, selling across three segments: Vision Care, Pharmaceuticals and Surgical. Vision Care covers contact lenses, lens-care products, vitamins and over-the-counter eye drops. Pharmaceuticals covers treatments for glaucoma, inflammation, dry eye and retinal disease. No peer group is set for this name in our coverage; the comparison the market draws is with Alcon, another eye-care company spanning vision care, pharmaceuticals and surgical devices.

Where does Bausch + Lomb Corp sit in the AI build-out?

Bausch + Lomb holds no seat in Rubin, our AI build-out index; it sits in our broader universe under healthcare, in the medical instruments and supplies sector. Bausch + Lomb holds no seat in Rubin or our other indices, and it carries no Closelook score; coverage here rests on price and chart structure alone.

Does Bausch + Lomb Corp pay a dividend?

No cash distribution shows in Bausch + Lomb Corp’s price series over the last three years. The share count rose 0.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for BLCO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Instruments & Supplies. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.